RCS - ValiRx PLC - ValiRX to attend 2015 BIO International Convention <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

15/07/2015 15:25

RNS Number : 7515L
ValiRx PLC
30 April 2015
ValiRx Plc
("ValiRx" or the "Company")
VALIRX INVITED TO JOIN LEADING LONDON-BASED AND BRITISH BIOTECH COMPANIES IN THE 'MARKET VISIT' TO THE 2015 BIO INTERNATIONAL CONVENTION IN PHILADELPHIA, WITH SUPPORT FROM THE MAYOR OF LONDON'S 'EXPORT PROGRAMME' AND THE DTI
London (April 30th 2015) - ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that the Company has been invited to join with leading UK biotechnology and biopharma facing businesses and to participate in the 'Market Visit' to the 2015 BIO International Convention in Philadelphia, Pennsylvania (14-18 June 2015). 
The Market Visit has been organised by the Mayor of London's Export Programme, in partnership with UK Trade & Investment (UKTI) to offer London SMEs an opportunity to attend this major industry international event and a chance to partner with the world's leading pharmaceutical and biotechnology companies. 
The Mayor's Export Programme delivered in partnership with UKTI and co-funded by the European Regional Development Fund (ERDF), seeks to increase the number of London's SMEs trading internationally by providing them with the requisite expertise, support and funding to start trading in new markets.
Last year's Convention featured more than 1,800 exhibitors and 55 state, regional and country pavilions in an area of over 160,000 square feet. The Convention was visited by attendees from leading biotech companies, top 25 pharma companies and more than 300 academic institutions, including research labs and government agencies. 
According to the 2013 Campbell Alliance's Deal Makers' Intentions report, most successful deals in the biopharma industry are a result of partnering events. The 2014 Convention held more than 28,000 partnering meetings between 3,166 companies in 3 days. 
Dr Satu Vainikka, CEO of ValiRx, commented:"I am delighted ValiRx has been invited to join an impressive British delegation of biotech businesses attending this major industry event. I look forward to the Company building its profile on the international stage, particularlyfollowing our successful poster presentation at the recent American Association for Cancer Research ("AACR") conference in Philadelphia and I look forward to ValiRx expanding its network of relationships to the benefit of our shareholders".
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0)20 3008 4416
Dr Satu Vainikka
www.ValiRx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0)20 7148 7900
Liam Murray / Avi Robinson



Daniel Stewart & Company Plc (Broker)
Tel: +44 (0)20 7776 6550
Martin Lampshire

Peckwater PR
Tel: +44 (0)7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk
Notes for Editors 
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company has undertaken todevelop a novel and groundbreaking class of therapeutics across a number offields in oncology and has taken its lead compound, Val201, into Phase I/IIclinicaltrials. The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases.
It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimising financial exposure andrunning a set of projects todefined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAILMATMBITBFA